Drug treatment of hypertension complicating diabetes mellitus

Drugs

Volumn 56, Issue 2, 1998, Pages 189-202

  MacLeod, Mary J ^a   McLay, James ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET THERAPY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MORTALITY; WEIGHT REDUCTION;

EID: 0031819648     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199856020-00003     Document Type: Article

References (97)

1. Bakris GL, Weir MR, Sowers JR. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med 1996; 101: 33S-46S
2. Tarnow L, Rossing P, Gall MA, et al. Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 1994; 17: 1247-51
3. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. Hypertension 1995; 26; 869-79
4. Garbar AJ. Effective treatment of hypertension in patients with diabetes mellitus. Clin Cardiol 1992; 15: 715-9
5. Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med 1996; 124: 110-6
6. Weidmann P, Bochlen LM, deCourten M, et al. Antihypertensive therapy in diabetic patients. J Hum Hypertens 1992; 6 Suppl. 2: S23-6
7. Epstein M, Sowers J. Diabetes mellitus and hypertension. Hypertension 1992; 19 (5): 403-18
8. Gall MA, Borch-Johnsen K, Hougaard P, et al. Albiminuria and poor glycaemic control predict mortality in NIDDM. Diabetes 1995; 44: 1303-9
9. Parving HH. Microalbuminuria in essential hypertension and diabetes mellitus. J Hypertens 1996; 14: S89-93
10. Hendry BM, Viberti GC, Hummel S, et al. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients. Q J Med 1997; 90: 277-82
11. Ritz E. Hypertension in diabetic nephropathy: prevention and treatment. Am Heart J 1993; 125: 1514-9
12. Slataper R, Bakris G. Slowing the course of renal failure in patients with diabetes. Drug Ther 1992; 5: 35-46
13. Lippert J, Ritz E, Schwarzbeck A, et al. The rising tide of endslage renal failure from diabetic nephropathy type II - an epidemiological analysis. Nephrol Dial Transplant 1995; 10: 462-7
14. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27: 167-94
15. Collaborative Study Group. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995; 311: 973-7
16. Hypertension in Diabetes Study (HDS) II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993 Mar; 11 (3): 319-25
17. Schernthaner G. Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Res Clin Pract 1996 Jul; 31 Suppl.: S3-13
18. Mehler PS, Jeffers BW, Estacio R, et al. Associations of hypertension and complications of non-insulin dependent diabetes mellitus. Am J Hypertens 1997; 10: 152-61
19. Gilbert R, Phillips P, Clarke C, et al. Day-night blood pressure variation in normotensive, microalbuminuric type I diabetic subjects: dippers and non-dippers. Diabetes Care 1994; 17: 824-7
20. Hansen KW, Poulsen PL, Mogensen CE. Ambulatory blood pressure and abnormal albuminuria in type I diabetic patients. Kidney Int 1994; 45: S134-40
21. National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 1994; 23: 145-58
22. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993; 306: 1313-8
23. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ 1985; 291: 97-104
24. Sixth Report of the Joint National Committee on the Detection. Evaluation and Treatment of High Blood Pressure (JNC VI). National Institutes of Health Publication No. 98-4080. Arch Intern Med 1997 Nov; 157 (21): 2413-46
25. Weidmann PO, Boehlen L, de Courten M. Pathogenesis and treatment of hypertension associated with diabetes mellitus. Am Heart J 1993; 125: 1498-513
26. Reaven GM. Insulin resistance and compensatory hyper-insulinaemia: role in hypertension, dyslipidaemia, and coronary heart disease. Am Heart J 1991; 121: 1283-8
27. Bengtsson C, Blohme G, Lapidus L. Do antihypertensive drugs precipitate diabetes? BMJ 1984; 289: 1495-7
28. Donahue R, Abbott R, Wilson P. Effect of diuretic use on the development of diabetes mellitus: the Framingham study. Horm Metab Res 1990; 22: 46-8
29. Rowe J, Tobin J, Rosa R, et al. Effects of experimental potassium deficiency on glucose and insulin metabolism. Metabolism 1980; 29: 498-502
30. Helderman J, Elahi D, Anderson D. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32: 106-11
31. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-73
32. Schmitz O, Hermansen K, Nielson O, et al. Insulin action in insulin-dependent diabetics after short term thiazide therapy. Diabetes Care 1986; 9: 631-6
33. Warram J, Laffel LM, Valsania P, et al. Excess mortality associated with diuretic therapy in diabetes mellitus. Arch Intern Med 1991; 151: 1350-6
34. Klein R, Moss SE, Lein BEK, et al. Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med 1989; 149: 266-72
35. Black HR, Cohen J, Davis BR, et al. Influence of long-term, low-dose, diuretic based antihypertensive therapy on glucose, lipid and mortality. Hypertension 1993; 21: 335-43
36. Gambardella S, Frontoni S, Lala A, et al. Regression of microalbuminuria in type II diabetic, hypertensive patients alter long term indapamide treatment. Am Heart J 1991; 122: 1232-8
37. Walker WG, Hermann JA, Anderson JE. Randomised double blinded trial of enalapril vs hydrochlorothiazide on glomerular filtration rate in diabetic nephropathy [abstract]. Hypertension 1993; 22: 410
38. Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983-7
39. Cerasi E, Luft R, Efendic S. Effect of adrenergic blocking agents on insulin response to glucose infusion in man. Acta Endocrinol 1972; 69: 335-46
40. Micossi P, Pollavini G, Raggi U, et al. Effects of metoprolol and propranolol on glucose tolerance and insulin secretion in diabetes mellitus. Horm Metab Res 1984; 16: 59-63
41. Waal-Manning H. Metabolic effects of beta adrenoceptor blockers. Drugs 1976; II Suppl. 1: 121-6
42. Clarke WL, Santiago JV, Thomas L, et al. Adrenergic mechanism in recovery from hypoglycemia in man: adrenergic blockade. Am J Physiol 1979; 236: E147-52
43. Totterman K, Groop L, Groop PH. Effect of beta blocking drugs on beta cell function and insulin sensitivity in hypertensive non diabetic patients. Eur J Clin Pharmacol 1984; 26: 13-7
44. Ferrara L, Capaldo B, Rivellese A, et al. Effects of beta receptor blockade on carbohydrate metabolism. J Hypertens 1985; 3 (3): S199-201
45. Bengtsson G, Blohme G, Lapidus L, et al. Diabetes incidence in users and non-users of anti-hypertensive drugs in relation to serum insulin, glucose tolerance, and degree of adiposity: a 12 year prospective population study of women in Gothenburg, Sweden. J Intern Med 1992; 231: 583-8
46. Lager I, Blohme G, Smith U. Effect of cardioselective and non-selective beta-blockade on the hypoglycemic response in insulin dependent diabetics. Lancet 1979; I: 458-62
47. Deacon SP, Barnett D. Comparison of atenolol and propranolol during insulin-induced hypoglycaemia. BMJ 1976; 2: 272-3
48. Cameron OG. Beta-adrenergic blockade does not prevent hypoglycaemic awareness in non-diabetic humans. Psychosom Med 1989; 51: 165-72
49. Kerr D, Macdonald IA, Heller SR, et al. Beta-adrenoceptor blockade and hypoglycaemia. Br J Clin Pharmacol 1990; 29: 264-70
50. Short RI, Ray WA, Daugherty JR, et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997; 278: 40-3
51. MIAMI Trial Research Group. Metoprotol in acute myocardial infarction: a randomised placebo-controlled international trial. Eur Heart J 1992; 13: 28-32
52. Smith HW, Marcus FI, Serokman R. Prognosis of patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol 1984; 54: 718-21
53. Zuanetti G, Latini R. Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients. J Diabet Complications 1997; 11 (2): 131-6
54. Yusef S, Lessem J, Jha P, et al. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens 1993; II: S61-73
55. Bjorck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339-43
56. Bakris GL, Copley JB, Vicknair N. Blood pressure reduction and progression of diabetic nephropathy in African Americans: a five year follow-up study [abstract]. J Am Soc Nephrol 1995; 6: 446A
57. Buller GK, Perazella M. ACE inhibitor-induced hypoglycaemia. Am J Med 1991; 91: 104-5
58. Umnerova V, Jarolim M, Jindra A. Control of hyperinsulinaemia in essential hypertension using the angiotensin-converting enzyme inhibitor, lisinopril. Cor Vasa 1993; 35: 75-9
59. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-62
60. Orth S, Nowicki M, Wiecek A, et al. Nephroprotective effect of ACE inhibitors. Drugs 1993; 46 Suppl. 2: 189-96
61. Hallab M, Gallois Y, Chatellier G, et al. Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. BMJ 1993; 306: 175-82
62. Bakris GL, Slataper R, Vicknair N, et al. ACE inhibitor mediated reductions in renal size and microalbuminuria in normotensive, diabetic subjects. J Diabet Complications 1994; 8: 2-6
63. Viberti G, Mogensen CE, Groop LC, et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994; 271: 275-9
64. Mathiesen E, Hommel E, Smith U, et al. Efficacy of captopril in normotensive diabetic patients with albuminuria: 8 years follow up [abstract]. Diabetologia 1995; 38: A46
65. Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 1988; 297: 1086-91
66. Gambardella S, Frontoni S, Lala A, et al. Regression of microalbuminuria in type II diabetic, hypertensive patients after long-term indapamide treatment. Am Heart J 1991; 122: 1232-78
67. Lacourciere Y, Nadeau A, Poirier L. Captopril or conventional therapy in hypertensive type II diabetics: three-year analysis. Hypertension 1993; 21: 786-94
68. Maki DD, Ma JZ, Louis TA, et al. Effects of antihypertensive agents on the kidney. Arch Intern Med 1995; 155: 1073-82
69. Bohlen L, de Courten M, Weidmann P. Comparative study of the effects of ACE inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 84S-92S
70. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial transplant 1995; 10: 39-45
71. Cooper ME. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients. J Hypertens 1996; 14: S11-4
72. Sawicki PT, Kaiser S, Heinemann L, et al. Prevalence of renal artery stenosis in diabetes mellitus an autopsy study. J Intern Med 1991 Jun; 229 (6): 489-92
73. Messerli FH, Soria F. Ventricular dysrhythmias, left ventricular hypertrophy and sudden death. Cardiovasc Drugs Ther 1994; 8: S557-63
74. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens 1995; 13: 1343-51
75. Kohzuki M, Yasujima M, Lin PF, et al. Cardiovascular and renal protective effects of losartan in spontaneously hypertensive rats with diabetes mellitus. Clin Exp Pharmacol Physiol 1995; Suppl. 1: S366-7
76. Laakso M, Karjalainen L, Lempiainen-Kuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392-6
77. Furberg CD, Pahor M, Psaty BM. The unnecessary controversy. Eur Heart J 1996; 17: 1142-7
78. Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645-52
79. Lyngsoe J, Sorensen M, Sjostrand H, et al. The effect of sustained release verapamil on glucose metabolism in patients with non-insulin dependent diabetes mellitus. Drugs 1992; 1: 85-7
80. Anderssen D, Rojdmark S. Improvement of glucose tolerance by verapamil in patients with non-insulin-dependent diabetes mellitus. Acta Med Scand 1981; 210: 27-33
81. Rossing P, Tarnow L, Boelskifte S, et al. Differences between nisoldipine and lisinopril on glomerular nitration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 1997; 46: 481-7
82. Parving HH, Tarnow L, Rossing P. Renal protection in diabetes: an emerging role for calcium antagonists. J Hypertens 1996; 14: S21-5
83. Hoelscher D, Bakris G. Antihypertensive therapy and progression of diabetic renal disease. J Cardiovasc Pharmacol 1995; 23: S34-8
84. Abbott K, Smith A, Bakris GL. Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol 1996; 36: 274-9
85. Munter K, Hergenroder S, Jochims K, et al. Individual and combined effects of verapamil or trandolapril on glomerular morphology and function in the stroke prone rat. Am J Soc Nephrol 1996; 7: 681-6
86. Gaber L, Walton C, Brown S, et al. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in nephrectomised dogs. Kidney Int 1994; 46: 161-9
87. Lievre M, Nony P. Calcium antagonists in the secondary prevention of myocardial infarction. Therapie 1993; 48: 677-83
88. Pahor M, Guralnik JM, Furberg CD, et al. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 147: 1061-5
89. Bakris GL, Williams B. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: does the progression of diabetic renal disease differ? J Hypertens 1995; 13: S95-101
90. Broadstone V, Pfeifer M, Bajaj V, et al. Alpha adrenergic blockade improves glucose potentiated insulin secretion in non insulin dependent diabetes mellitus. Diabetes 1987; 36: 932-7
91. Shionoiri H, Gotoh E, Ito T. Long term therapy with terazosin may improve glucose and lipid metabolism in hypertensives: a multicenter prospective study. Am J Med Sci 1994; 307: S91-5
92. Itslovitz HD. Alpha I blockade for the treatment of hypertension: a mega study of terazosin in 2214 clinical practice settings. Clin Ther 1994; 16: 490-504
93. Levy P, Effects of prazosin on blood pressure and diabetic control in patients with type II diabetes mellitus and mild essential hypertension. Am J Med 1989; 86: 59-62
94. Jyothirmayi GN, Alluru I, Reddi AS. Doxazosin prevents proteinuria and glomerular loss of heparan sulfate in diabetic rats. Hypertension 1996; 27: 1108-14
95. Feher MD. Doxazosin therapy in the treatment of diabetic hypertension. Am Heart J 1991; 121: 1291-301
96. Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995; 8: 316-20
97. Wise J. Diabetes drug withdrawn after reports of hepatic events. BMJ 1997; 315: 1564